MILOPHENE Drug Patent Profile
Which patents cover Milophene, and when can generic versions of Milophene launch?
Milophene is a drug marketed by Granata Bio Corp and is included in one NDA.
The generic ingredient in MILOPHENE is clomiphene citrate. There is one drug master file entry for this compound. Eleven suppliers are listed for this compound. Additional details are available on the clomiphene citrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Milophene
A generic version of MILOPHENE was approved as clomiphene citrate by APPCO on November 8th, 2024.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MILOPHENE?
- What are the global sales for MILOPHENE?
- What is Average Wholesale Price for MILOPHENE?
Summary for MILOPHENE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 55 |
| Clinical Trials: | 1 |
| Patent Applications: | 1,606 |
| Drug Prices: | Drug price information for MILOPHENE |
| DailyMed Link: | MILOPHENE at DailyMed |
Recent Clinical Trials for MILOPHENE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Weill Medical College of Cornell University | Phase 2 |
Pharmacology for MILOPHENE
| Drug Class | Estrogen Agonist/Antagonist |
| Mechanism of Action | Selective Estrogen Receptor Modulators |
US Patents and Regulatory Information for MILOPHENE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Granata Bio Corp | MILOPHENE | clomiphene citrate | TABLET;ORAL | 072196-001 | Dec 20, 1988 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
